Trial Profile
Drug Use Surveillance for ADCETRIS Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- Sponsors Takeda
- 13 Dec 2022 Status changed from active, no longer recruiting to completed.
- 24 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 23 Mar 2021 Planned End Date changed from 31 May 2022 to 31 Dec 2022.